Oban BioPharma
↗Stamford, USA
Oban BioPharma is a biotechnology company focused on the discovery and development of next-generation allosteric and biased oral GPCR therapeutics. The company utilizes a proprietary AI-driven platform that combines computational structural analysis with high-dimensional 'druggability' filters to map allosteric pockets and screen billions of structures in silico.
Founded by the leadership team behind Cara Therapeutics and Arena Pharmaceuticals, Oban targets high-value indications in Central Nervous System (CNS) and metabolic diseases. Their lead programs focus on muscarinic M4 receptor modulators for neuropsychiatric conditions and small molecule GLP-1 mimics for metabolic disorders.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue
Founded:2023
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$11.5M
Investors:Apple Core Holdings
PIPELINE
Stage:Preclinical
Lead Drug Stage:IND-enabling
Modalities:Small molecule, Allosteric modulators (Ago-PAMs)
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Choyce Peterson (Real Estate/HQ strategy)
COMPETITION
Position:Emerging
Competitors:Bristol Myers Squibb (Karuna Therapeutics - Cobenfy), AbbVie (Cerevel Therapeutics - Emraclidine), Sosei Heptares, Structure Therapeutics
LEADERSHIP
Key Executives:
Derek Chalmers, Ph.D., D.Sc. - President & CEO
Michael Lewis, Ph.D. - Chief Scientific Officer
Scientific Founders:Derek Chalmers, Michael Lewis
Board Members:Derek Chalmers, Michael Lewis
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Oban BioPharma. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.